Biopharma's winners and losers of 2025
2025年生物医药业的赢家与输家
What a year! The XBI is up, M&A is bumping and the vibes are improving. But it ain’t all Christmas cookies. As has become our tradition, we kept track of who was up and who was down in 2025 to take stock of the year in ideas, people, drugs and companies.
多事之秋！XBI走高，兼并收购回暖，市场情绪也在转好。但并非尽是圣诞甜饼。照例，我们统计了2025年里在创意、人物、药物与公司层面谁在上行、谁在下行，以盘点这一年的风向。
本报道最初发表于Endpoints News。请点击这里查看原文
What a year! The XBI is up, M&A is bumping and the vibes are improving. But it ain’t all Christmas cookies. As has become our tradition, we kept track of who was up and who was down in 2025 to take stock of the year in ideas, people, drugs and companies.
真是精彩的一年！XBI上涨，M&A活跃，整体氛围在好转。不过也不全是“圣诞曲奇”。按照我们的惯例，我们梳理了2025年里谁在上行、谁在下行，总结这一年的创意、人物、药物与公司。
您已阅读4%（374字），剩余96%（8550字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。